Dianthus Therapeutics’ claseprubart has met its primary and secondary endpoints during a Phase II trial in generalised myasthenia gravis (gMG). During the MaGic study (NCT06282159), the active ...
Alnylam Scientists Present Pre-clinical Data with ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases – New Research Presented at 6 th ...
The complement system is primarily a host defence mechanism, but it causes injury to tissue cells through the formation of the membrane attack complex (C5b–C9), which leads to cell lysis and cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results